Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial

Conclusions
The overall benefits of dabigatran for stroke/SE prevention, and major and intracranial bleeding, relative to warfarin in the RE-LY trial were consistent in patients with and without HF.

Source: European Journal of Heart Failure - August 19, 2013 Category: Cardiology Authors: Ferreira, J., Ezekowitz, M. D., Connolly, S. J., Brueckmann, M., Fraessdorf, M., Reilly, P. A., Yusuf, S., Wallentin, L., on behalf of the RE-LY Investigators Tags: TREATMENT Source Type: research